Outcome-Based Risk Assessment of Non-HLA Antibodies in Heart Transplantation: A Systematic Review
AJ Panicker, LJ Prokop, K Hacke, A Jaramillo… - The Journal of Heart and …, 2024 - Elsevier
Background Current monitoring after heart transplantation (HT) employs repeated invasive
endomyocardial biopsies (EMB). Although positive EMB confirms rejection, EMB fails to …
endomyocardial biopsies (EMB). Although positive EMB confirms rejection, EMB fails to …
[HTML][HTML] Everolimus plus reduced calcineurin inhibitor prevents de novo anti-HLA antibodies and humoral rejection in kidney transplant recipients: 12-month results …
W Arns, A Philippe, V Ditt, IA Hauser… - Frontiers in …, 2023 - frontiersin.org
Background Studies prospectively monitoring de novo donor-specific antibodies (dnDSAs)
and their clinical impact are sparse. This substudy of ATHENA was initiated to evaluate the …
and their clinical impact are sparse. This substudy of ATHENA was initiated to evaluate the …